B-cell & Hematologic Antigens

Cat. No.

AT0430

Ianalumab (FUT8-KO)

Ianalumab (FUT8-KO) is an anti-BAFF-R monoclonal antibody, produced in Chinese Hamster Ovary (CHO) cells with a targeted knockout of the fucosyltransferase 8 gene (FUT8). The absence of fucose on this antibody significantly enhances its Antibody-Dependent Cellular Cytotoxicity (ADCC) capabilities. This antibody effectively blocks the interaction between B-cell Activating Factor (BAFF) and its receptor BAFF-R, thereby inhibiting the BAFF-mediated apoptotic protection. This makes Ianalumab (FUT8-KO) a valuable tool for research into BAFF-R related signaling pathways and potential therapeutic interventions in autoimmune diseases and malignancies where BAFF and BAFF-R interactions play a critical role.

Cat. No.

AT0437

CAS No.

244096-20-6

Gavilimomab

Synonyms: ABX-CBL

Gavilimomab (ABX-CBL) is an IgM murine monoclonal antibody designed to target CD147, a cell surface antigen. This antibody facilitates cell death via complement-mediated lysis. It is primarily utilized in the study of graft-versus-host disease (GVHD), offering a valuable tool for researchers investigating the pathophysiology and potential therapeutic interventions of this condition.

Cat. No.

AT0438

AGS-67E

AGS-67E is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting TSPAN26/CD37. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of 143.44 kDa. For experimental control purposes, Human IgG2 kappa, Isotype Control is recommended. AGS-67E is applicable for a range of research studies focusing on the biological functions and therapeutic targeting of TSPAN26/CD37.

Cat. No.

AT0466

CAS No.

1299440-37-1

Inebilizumab

Inebilizumab is a monoclonal antibody targeting CD19 with enhanced capabilities for antibody-dependent cell-mediated cytotoxicity (ADCC) directed against B cells. This antibody is utilized in research focused on multiple sclerosis and neuromyelitis optica, providing a valuable tool for studying disease mechanisms and potential therapeutic interventions in these conditions.

Cat. No.

AT0468

Anti-CD2 Antibody (CB.219)

The Anti-CD2 Antibody (CB.219) is a chimeric mouse monoclonal antibody of the IgG2b, κ subclass, specifically designed to target human CD2. This antibody is ideal for research applications requiring precise CD2 modulation or detection. For accurate experimental control, it is recommended to use the Mouse IgG2b kappa, Isotype Control.

Cat. No.

AT0488

CAS No.

1826831-79-1

Talacotuzumab

Synonyms: JNJ 56022473; CSL 362

Talacotuzumab (JNJ 56022473; CSL 362) is a fully humanized IgG1 monoclonal antibody engineered to neutralize CD123. It exhibits dissociation constants (K_Ds) of 0.43 nM for CD123, 188 nM for CD32b/c, 46 nM for CD16-158F, and 16.8 nM for CD16-158V, indicating high specificity and affinity for these targets. The antibody effectively inhibits interleukin-3 (IL-3) binding to CD123, thereby blocking IL-3 mediated signaling pathways in targeted cells. The Fc region of Talacotuzumab has been specifically mutated to enhance its affinity for CD16 (FcγRIIIa), which significantly amplifies its capability to mediate antibody-dependent cell-mediated cytotoxicity (ADCC). This modification enhances its therapeutic potential, particularly in oncology applications. In vivo studies demonstrate that Talacotuzumab significantly reduces leukemic cell proliferation in acute myeloid leukemia (AML) xenograft mouse models, highlighting its potential as a therapeutic agent in hematological malignancies.

Cat. No.

AT0514

CAS No.

288392-69-8

Siplizumab

Synonyms: MEDI-507

Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody that targets CD2, a cell surface antigen predominantly expressed on T cells. This antibody functions by depleting T cells, reducing their activation, and inhibiting their proliferation. Additionally, Siplizumab promotes the enrichment of naïve and bona fide regulatory T cells. It is utilized primarily in research focused on immunological tolerance, autoimmunity, and transplantation immunology.

Cat. No.

AT0532

CAS No.

1169956-08-4

Ocaratuzumab

Synonyms: AME 133v; LY 2469298; Humanized Anti-MS4A1 Recombinant Antibody

Ocaratuzumab (AME 133v) is an Fc-engineered, humanized IgG1 monoclonal antibody targeting CD20, characterized by a dissociation constant (Kd) of approximately 100 pM. This antibody demonstrates enhanced efficacy in antibody-dependent cell-mediated cytotoxicity (ADCC), making it a potent candidate for research in immune-mediated therapeutic strategies.

Cat. No.

AT0533

CAS No.

1174014-05-1

Ublituximab

Synonyms: LFB-R603; TG-1101; TGTX-1101

Ublituximab, also known as LFB-R603, TG-1101, and TGTX-1101, represents a next-generation, type 1 chimeric monoclonal antibody designed to selectively bind to a unique epitope on the CD20 antigen. This targeting facilitates the induction of cytotoxic effects against CD20-expressing B cells, commonly implicated in various hematological malignancies. Ublituximab's mechanism of action and specificity make it a valuable tool in the research and treatment of cancer.

Cat. No.

AT0554

CAS No.

152923-56-3

Daclizumab

Synonyms: Zenapax; Ro 24-7375

Daclizumab (Zenapax) is a humanized monoclonal antibody designed to specifically target and block CD25, the α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA). By reversibly binding to CD25, Daclizumab inhibits the interaction between interleukin-2 (IL-2) and its receptor, thereby modulating the immune response. This antibody is primarily utilized in research focused on multiple sclerosis, providing a valuable tool for investigating the pathophysiology and potential therapeutic interventions in this disease.

Cat. No.

AT0559

CAS No.

356547-88-1

Belimumab

Synonyms: LymphoStat B

Belimumab, also known as LymphoStat-B, is a humanized IgG1λ monoclonal antibody designed to target and neutralize B-lymphocyte stimulator (BLyS) protein. By antagonizing the activity of BLyS, Belimumab is utilized in the study of autoimmune disorders and B-cell malignancies. This antibody is particularly relevant for research focused on systemic lupus erythematosus (SLE), providing a valuable tool for understanding and potentially modulating disease mechanisms.

Cat. No.

AT0591

CAS No.

915296-00-3

Elotuzumab

Synonyms: HuLuc 63; PDL 063; BMS 901608

Elotuzumab is a monoclonal antibody that specifically targets the SLAMF7 receptor. While it demonstrates minimal antimyeloma activity as a monotherapy in cases of relapsed or refractory multiple myeloma (RRMM), its efficacy is significantly enhanced when used in conjunction with other antimyeloma agents. This combination therapy has been shown to improve both response rates and overall outcomes in multiple myeloma treatment.

Cat. No.

AT0597

CAS No.

2919583-43-8

Imneskibart

Imneskibart is a humanized IgG1κ monoclonal antibody specifically targeting IL-2RA. For experimental control, the recommended isotype control is Human IgG1 kappa Isotype Control.

Cat. No.

AT0611

CAS No.

2249927-04-4

Ripertamab

Synonyms: SCT400

Ripertamab (SCT400) is a recombinant, chimeric monoclonal antibody (mAb) composed of human and mouse sequences. This antibody is of the IgG1κ isotype and targets the CD20 antigen, a cell surface protein primarily expressed on B cells. Ripertamab is specifically designed for use in research focused on hematological malignancies, such as non-Hodgkin’s lymphoma (NHL), providing a valuable tool for studies aimed at understanding and potentially treating these diseases.

Cat. No.

AT0625

CAS No.

679818-59-8

Ofatumumab

Ofatumumab is a fully human monoclonal antibody targeting the CD20 antigen on B lymphocytes. It functions primarily through the induction of antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), effectively lysing CD20-positive B cells. This antibody demonstrates potent efficacy in eliminating CD20-positive tumor cells, including those resistant to other drugs with low CD20 expression levels. Ofatumumab is particularly valuable in the study of chronic lymphocytic leukemia (CLL), offering insights into therapeutic resistance and disease progression mechanisms.

Cat. No.

AT0663

CAS No.

921618-45-3

Camidanlumab

Synonyms: HuMax-TAC

Camidanlumab (HuMax-TAC) is a monoclonal antibody specifically targeting CD25, a cell-surface antigen prominently overexpressed in various hematological malignancies, while exhibiting minimal expression in normal tissues. This selective expression profile makes Camidanlumab an ideal candidate for the development of antibody-drug conjugates (ADCs) aimed at treating diseases such as lymphoma and leukemia. This antibody facilitates targeted therapeutic delivery, potentially enhancing treatment efficacy and reducing systemic toxicity.

Cat. No.

AT0672

CAS No.

1622327-39-2

Naratuximab

Synonyms: Anti-TSPAN26/CD37 Reference Antibody (naratuximab

Naratuximab is a humanized monoclonal antibody specifically targeting CD37 (TSPAN26), a tetraspanin protein widely expressed on the surface of B cells. This antibody exhibits high specificity and affinity for CD37, making it an ideal candidate for targeted therapeutic applications, including the development of antibody-drug conjugates (ADCs). Naratuximab serves as the foundation for the ADC compound Naratuximab emtansine, which combines the targeted binding properties of naratuximab with the cytotoxic agent emtansine, offering potential applications in the treatment of B-cell malignancies.

Cat. No.

AT0697

SAR-442257

SAR442257 is a humanized IgG4-S228P kappa monoclonal antibody designed to specifically target CD38 and CD28 antigens expressed on multiple myeloma cells. Additionally, this antibody co-stimulates CD3 and CD28 on T cells, enhancing immune response. This dual targeting and co-stimulation mechanism makes SAR442257 a valuable tool for research in immunotherapy and the study of multiple myeloma pathogenesis.

Cat. No.

AT0712

KHK-2898

Anti-CD98 monoclonal antibody (Clone KHK2898) specifically targets CD98, a protein implicated in amino acid transport and integrin signaling. This antibody is ideal for research applications aiming to elucidate the role of CD98 in cellular processes such as nutrient uptake, cell adhesion, and tumor progression.

Cat. No.

AT0726

CAS No.

2254061-60-2

Divozilimab

Synonyms: BCD-132

Divozilimab (BCD-132) is a humanized monoclonal antibody specifically targeting CD20, a cell surface protein primarily expressed on B lymphocytes. This antibody is utilized extensively in the study of multiple sclerosis, aiding in the exploration of B-cell mediated pathogenesis and potential therapeutic interventions.

Cat. No.

AT0733

Anti-CD4 Antibody (Hu5A8)

The Anti-CD4 Antibody (Hu5A8) is a humanized IgG4 monoclonal antibody designed to specifically target CD4, a critical molecule involved in the immune response and a key marker on helper T cells. For rigorous experimental control, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This antibody is optimal for research applications seeking to elucidate the role of CD4 in immune function and pathology.

Cat. No.

AT0738

CAS No.

1165740-62-4

Vorsetuzumab

Vorsetuzumab, a recombinant human anti-CD70 antibody, targets the CD70 antigen expressed on various tumor cells. This antibody has been shown to enhance macrophage-mediated phagocytosis of renal carcinoma cells and exhibit inhibitory effects on Burkitt’s lymphoma. Vorsetuzumab holds significant potential for therapeutic applications in oncology, particularly in the treatment of renal carcinoma and Burkitt’s lymphoma, by modulating immune responses against tumor cells.

Cat. No.

AT0776

CAS No.

1849636-24-3

Tibulizumab

Synonyms: LY 3090106

Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody designed for dual targeting of B-cell activating factor (BAFF) and interleukin-17A (IL-17A), exhibiting high affinity with dissociation constants (Kd) of 60 pM and 14 pM, respectively. This antibody is specifically engineered for the study of autoimmune diseases, providing a valuable tool for investigating the pathophysiological roles of BAFF and IL-17A in immune modulation and inflammation.

Cat. No.

AT0790

Anti-E-Selectin Antibody (CL2)

Anti-E-Selectin Antibody (CL2) is a chimeric mouse monoclonal antibody of the IgG2a, κ subtype, specifically designed to target human E-Selectin. For accurate isotype control in experimental procedures, it is recommended to use Mouse IgG2a kappa Isotype Control. This antibody is ideal for researchers studying cellular adhesion processes, inflammation, and vascular biology.

Cat. No.

AT0800

CAS No.

158318-63-9

Bectumomab

Synonyms: IMMU-LL 2

Bectumomab (IMMU-LL 2) is a humanized IgG2a monoclonal antibody specifically targeting human CD22, an antigen predominantly expressed on the surface of B cells. This antibody is engineered as an anti-lymphoma agent, primarily utilized in the detection and management of non-Hodgkin's lymphoma (NHL). Bectumomab is compatible for use in imaging studies when conjugated with technetium-99 (Tc99m LL2 Fab), facilitating the assessment of lymphoma staging in both recurrent and newly diagnosed cases. Additionally, it serves as a valuable tool in evaluating the efficacy of targeting prior to the initiation of radioimmunotherapy (RIT). This antibody's specificity and application in advanced diagnostic imaging and therapy make it a critical component in lymphoma research and clinical practice.